Contact Us

What experience does Abingdon Health have in regulated markets?

Abingdon Health has significant experience developing and manufacturing rapid tests and readers in both regulated and non-regulated markets.

Abingdon Health was responsible for launching a lateral flow test for multiple myeloma (blood cancer), and led the UK Rapid Test Consortium in developing and manufacturing a COVID-19 rapid antibody test.

Whether working in regulated or non-regulated markets Abingdon Health’s adheres to the following quality management systems:

  • ISO 13485
  • ISO 9001
  • Good Manufacture Practice (GMP)

Visit our quality standards page to learn more about how Abingdon Health operates under ISO and GMP quality management systems.

Case studies

AbC-19 Rapid Test logoAs mentioned above, Abingdon Health led the development and manufacture of a rapid test that detects neutralising antibodies to SARS-CoV-2. The UK Government entered into a contract with Abingdon Health to use the rapid test, which is called AbC-19TM.

Read the AbC-19TM Whitepaper.

Also, read how Abingdon Health developed a rapid test for the quantification of kappa and lambda free light chains.

Back to FAQs